ClinicalTrials.gg
CompletedNCT00321464Updated Nov 8, 2022Results posted

A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

A Phase 3 interventional study of Denosumab and Zoledronic Acid in Bone Metastases, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Amgen · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,049
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone metastases in subjects with advanced breast cancer.

02

Conditions studied

  • Bone Metastases

Keywords

  • Fractures
  • Compressions
  • Bisphosphonates
  • Bone metastases
  • Breast cancer
  • Skeletal
  • Radiation
  • Surgery to Bone
03

In context

Fractures, Bone

725 studies on the registry are indexed under Fractures, Bone; 116 are open to participants now.

This study's enrollment of 2,049 is above the median of 80 across 458 interventional studies indexed under Fractures, Bone.

Browse Fractures, Bone studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with or cytologically confirmed breast adenocarcinoma
  • radiographic evidence of at least one bone mets
  • Easter Cooperative Oncology Group status of 0, 1 or 2;
  • adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Current or prior IV bisphosphonate administration
  • current or prior oral bisphosphonates for bone mets
  • of less than 6 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2,049 participants (actual)

Study arms

  • Active comparator
    zoledronic acid

    Drug: Zoledronic Acid

  • Experimental
    denosumab

    Biological: Denosumab

Interventions

  • BiologicalDenosumab

    Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes

  • Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC

    Also known as: Zometa

06

What researchers measure

Primary outcomes

  1. Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority)

    Time to first on-study skeletal-related event (SRE) using a non-inferiority analysis. The median time to first skeletal-related event could not be estimated in one treatment arm, so the subject incidence is presented.

    Time frame: Up to 34 months

Secondary outcomes

  1. Time to First On-Study Skeletal-Related Event (Superiority)

    Time to first on-study skeletal-related event (SRE) using a superiority analysis. The median time to first skeletal-related event could not be estimated in one treatment arm, so the subject incidence is presented.

    Time frame: Up to 34 months

  2. Time to First and Subsequent On-Study Skeletal-Related Event

    Time to first and subsequent on-study skeletal-related event (SRE) using a multiple event analysis. To be considered a subsequent SRE, the event must occur at least 21 days after the previous SRE. This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative number of events.

    Time frame: Up to 34 months

07

Results

Posted Mar 10, 2014

Participant flow

Participants were enrolled from 27 April 2006 through 31 December 2007

Participant flow — Overall Study
MilestoneZoledronic AcidDenosumab
Started10201026
Received investigational product10141019
Completed461468
Not completed559558
Withdrew: Death169174
Withdrew: Disease progression124124
Withdrew: Withdrawal by subject117118
Withdrew: Participant request5761
Withdrew: Adverse event4328
Withdrew: Physician decision1514
Withdrew: Noncompliance410
Withdrew: Lost to follow-up78
Withdrew: Protocol deviation02
Withdrew: Ineligibility determined21
Withdrew: Other2118

Outcome measures

PrimaryTime to First On-Study Skeletal Related Event (SRE) (Non-inferiority)

Time to first on-study skeletal-related event (SRE) using a non-inferiority analysis. The median time to first skeletal-related event could not be estimated in one treatment arm, so the subject incidence is presented.

Time frame:
Up to 34 months
Reported as:
Number · Participants
Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority)
ParticipantsZoledronic AcidDenosumab
Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority)372315
Statistical analysis
  • Zoledronic Acid vs Denosumab · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 0.82 · 95% CI 0.71 to 0.95Stratified by the randomization stratification factors (previous skeletal-related event, prior oral bisphosphonate use, current chemotherapy, and location in Japan).
SecondaryTime to First On-Study Skeletal-Related Event (Superiority)

Time to first on-study skeletal-related event (SRE) using a superiority analysis. The median time to first skeletal-related event could not be estimated in one treatment arm, so the subject incidence is presented.

Time frame:
Up to 34 months
Reported as:
Number · Participants
Time to First On-Study Skeletal-Related Event (Superiority)
ParticipantsZoledronic AcidDenosumab
Time to First On-Study Skeletal-Related Event (Superiority)372315
Statistical analysis
  • Zoledronic Acid vs Denosumab · Regression, Cox · p = 0.010 (P-value was adjusted for multiplicity according to a hierarchical testing strategy and Hochberg procedure) · Hazard ratio (hr): 0.82 · 95% CI 0.71 to 0.95Stratified by the randomization stratification factors (previous skeletal-related event, prior oral bisphosphonate use, current chemotherapy, and location in Japan).
SecondaryTime to First and Subsequent On-Study Skeletal-Related Event

Time to first and subsequent on-study skeletal-related event (SRE) using a multiple event analysis. To be considered a subsequent SRE, the event must occur at least 21 days after the previous SRE. This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative number of events.

Time frame:
Up to 34 months
Reported as:
Number · Events
Time to First and Subsequent On-Study Skeletal-Related Event
EventsZoledronic AcidDenosumab
Time to First and Subsequent On-Study Skeletal-Related Event608474
Statistical analysis
  • Zoledronic Acid vs Denosumab · Anderson-Gill model · p = 0.001 (P-value was adjusted for multiplicity according to a hierarchical testing strategy and Hochberg procedure) · Rate ratio: 0.77 · 95% CI 0.66 to 0.89Stratified by the randomization stratification factors (previous skeletal-related event, prior oral bisphosphonate use, current chemotherapy, and location in Japan).

Adverse events

Collected over up to 2 years 10 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zoledronic Acid 4 mg Q4W—471/1,013 (46.5%)941/1,013 (92.9%)
Denosumab 120 mg Q4W—453/1,020 (44.4%)924/1,020 (90.6%)
Most frequent serious events
Showing 10 of 535
Most frequent serious events
EventZoledronic Acid 4 mg Q4WDenosumab 120 mg Q4W
DyspnoeaRespiratory, thoracic and mediastinal disorders38/101353/1020
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)46/101347/1020
AnaemiaBlood and lymphatic system disorders32/101327/1020
VomitingGastrointestinal disorders31/101331/1020
Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps)28/101320/1020
PyrexiaGeneral disorders26/101321/1020
PneumoniaInfections and infestations25/101320/1020
Pleural effusionRespiratory, thoracic and mediastinal disorders25/101324/1020
DehydrationMetabolism and nutrition disorders24/101313/1020
Hepatic failureHepatobiliary disorders16/101324/1020
Most frequent other events
Showing 10 of 55
Most frequent other events
EventZoledronic Acid 4 mg Q4WDenosumab 120 mg Q4W
NauseaGastrointestinal disorders377/1013350/1020
FatigueGeneral disorders323/1013291/1020
ArthralgiaMusculoskeletal and connective tissue disorders289/1013246/1020
Back painMusculoskeletal and connective tissue disorders256/1013238/1020
Bone painMusculoskeletal and connective tissue disorders233/1013181/1020
PyrexiaGeneral disorders231/1013157/1020
VomitingGastrointestinal disorders225/1013199/1020
DiarrhoeaGastrointestinal disorders198/1013223/1020
Pain in extremityMusculoskeletal and connective tissue disorders221/1013199/1020
AnaemiaBlood and lymphatic system disorders217/1013183/1020

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Zoledronic AcidDenosumabTotal
Mean56.6 ± 11.656.8 ± 11.556.7 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Zoledronic AcidDenosumabTotal
Female101110182029
Male9817
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zoledronic AcidDenosumabTotal
White or Caucasian8138221635
Black or African American252651
Hispanic or Latino5959118
Asian373269
Japanese6970139
Native Hawaiian or Other Pacific Islander112
Other161632
Previous Skeletal-Related Event Stratification Factor
Previous Skeletal-Related Event Stratification Factor(Participants)Zoledronic AcidDenosumabTotal
Yes373378751
No6476481295
Prior Oral Bisphosphonate Use Stratification Factor
Prior Oral Bisphosphonate Use Stratification Factor(Participants)Zoledronic AcidDenosumabTotal
Yes384280
No9829841966
Current Chemotherapy Stratification Factor
Current Chemotherapy Stratification Factor(Participants)Zoledronic AcidDenosumabTotal
Yes408410818
No6126161228
Japan Stratification Factor
Japan Stratification Factor(Participants)Zoledronic AcidDenosumabTotal
Yes6769136
No9539571910
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer. 2013 Feb 15;119(4):832-8. doi: 10.1002/cncr.27789. Epub 2012 Sep 5. PubMed 22951813 ↗
  • Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res. 2012 Sep 1;18(17):4841-9. doi: 10.1158/1078-0432.CCR-11-3310. Epub 2012 Aug 14. PubMed 22893628 ↗
  • Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010 Dec 10;28(35):5132-9. doi: 10.1200/JCO.2010.29.7101. Epub 2010 Nov 8. PubMed 21060033 ↗
  • Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martin M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016 Jan;24(1):447-455. doi: 10.1007/s00520-015-2904-5. Epub 2015 Sep 3. Erratum In: Support Care Cancer. 2016 Jan;24(1):457-458. doi: 10.1007/s00520-015-2985-1. PubMed 26335402 ↗
  • Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damiao R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer. 2015 Sep;51(13):1812-21. doi: 10.1016/j.ejca.2015.05.016. Epub 2015 Jun 17. PubMed 26093811 ↗
  • Diel IJ, Body JJ, Stopeck AT, Vadhan-Raj S, Spencer A, Steger G, von Moos R, Goldwasser F, Feng A, Braun A. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Eur J Cancer. 2015 Jul;51(11):1467-75. doi: 10.1016/j.ejca.2015.04.017. Epub 2015 May 11. PubMed 25976743 ↗
  • von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer. 2013 Dec;21(12):3497-507. doi: 10.1007/s00520-013-1932-2. Epub 2013 Aug 22. PubMed 23975226 ↗
  • Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10. PubMed 22975218 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2006 to primary completion in Jul 2009, 39 months.

Results were first posted in Mar 2014, 4 years 7 months after primary completion. A results delay was requested in Jun 2010.

Of 14 phase 3 interventional studies under Fractures, Bone, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 46. This study's 39 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2006
First posted
May 3, 2006
StartActual
Apr 1, 2006
Primary completionActual
Jul 20, 2009
CompletionActual
Apr 4, 2012
Results delay requested
Jun 29, 2010
Results first posted
Mar 10, 2014
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00321464
Lead sponsor
Amgen
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
May 3, 2006
Start date
Apr 1, 2006
Primary completion
Jul 20, 2009
Completion
Apr 4, 2012
Results posted
Mar 10, 2014
Last update
Nov 8, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion